Lexicon Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.49
- Today's High:
- $1.54
- Open Price:
- $1.53
- 52W Low:
- $1.49
- 52W High:
- $3.79
- Prev. Close:
- $1.52
- Volume:
- 749413
Company Statistics
- Market Cap.:
- $372.29 million
- Book Value:
- 0.761
- Revenue TTM:
- $407000
- Operating Margin TTM:
- -31635.14%
- Gross Profit TTM:
- $-52677000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -37.51%
- Return on Equity TTM:
- -101.65%
Company Profile
Lexicon Pharmaceuticals Inc had its IPO on 2000-04-07 under the ticker symbol LXRX.
The company operates in the Healthcare sector and Biotechnology industry. Lexicon Pharmaceuticals Inc has a staff strength of 135 employees.
Stock update
Shares of Lexicon Pharmaceuticals Inc opened at $1.53 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.49 - $1.54, and closed at $1.52.
This is a 0% increase from the previous day's closing price.
A total volume of 749,413 shares were traded at the close of the day’s session.
In the last one week, shares of Lexicon Pharmaceuticals Inc have slipped by -10.06%.
Lexicon Pharmaceuticals Inc's Key Ratios
Lexicon Pharmaceuticals Inc has a market cap of $372.29 million, indicating a price to book ratio of 2.8961 and a price to sales ratio of 3215.891.
In the last 12-months Lexicon Pharmaceuticals Inc’s revenue was $407000 with a gross profit of $-52677000 and an EBITDA of $-128288000. The EBITDA ratio measures Lexicon Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lexicon Pharmaceuticals Inc’s operating margin was -31635.14% while its return on assets stood at -37.51% with a return of equity of -101.65%.
In Q2, Lexicon Pharmaceuticals Inc’s quarterly earnings growth was a negative -63.4% while revenue growth was a positive 805.7%.
Lexicon Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- -0.14
Its diluted EPS in the last 12-months stands at $-0.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of -0.14. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lexicon Pharmaceuticals Inc’s profitability.
Lexicon Pharmaceuticals Inc stock is trading at a EV to sales ratio of 2492.0711 and a EV to EBITDA ratio of -3.2911. Its price to sales ratio in the trailing 12-months stood at 3215.891.
Lexicon Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $316.72 million
- Total Liabilities
- $26.11 million
- Operating Cash Flow
- $-74608000.00
- Capital Expenditure
- $139000
- Dividend Payout Ratio
- 0%
Lexicon Pharmaceuticals Inc ended 2024 with $316.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $316.72 million while shareholder equity stood at $-1666558000.00.
Lexicon Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $26.11 million in other current liabilities, 245000.00 in common stock, $-1666558000.00 in retained earnings and $44.54 million in goodwill. Its cash balance stood at $102.27 million and cash and short-term investments were $256.74 million. The company’s total short-term debt was $1,291,000 while long-term debt stood at $98.77 million.
Lexicon Pharmaceuticals Inc’s total current assets stands at $263.72 million while long-term investments were $0 and short-term investments were $154.47 million. Its net receivables were $685000.00 compared to accounts payable of $10.50 million and inventory worth $172000.00.
In 2024, Lexicon Pharmaceuticals Inc's operating cash flow was $-74608000.00 while its capital expenditure stood at $139000.
Comparatively, Lexicon Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.52
- 52-Week High
- $3.79
- 52-Week Low
- $1.49
- Analyst Target Price
- $5.77
Lexicon Pharmaceuticals Inc stock is currently trading at $1.52 per share. It touched a 52-week high of $3.79 and a 52-week low of $3.79. Analysts tracking the stock have a 12-month average target price of $5.77.
Its 50-day moving average was $1.9 and 200-day moving average was $2.27 The short ratio stood at 10.5 indicating a short percent outstanding of 0%.
Around 95.7% of the company’s stock are held by insiders while 7369.5% are held by institutions.
Frequently Asked Questions About Lexicon Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.